# SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD Subjects

> **NCT02307162** · PHASE1 · COMPLETED · sponsor: **Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA** · enrollment: 112 (actual)

## Conditions studied

- Inflammatory Disorder of the Respiratory Tract
- Chronic Obstructive Pulmonary Disorder

## Interventions

- **DRUG:** RPL554
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02307162
- **Lead sponsor:** Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2015-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02307162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02307162, "SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02307162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*